Sanofi Looks To Lead In Consumer Following Trade With Boehringer Ingelheim
This article was originally published in The Pink Sheet Daily
Sanofi will trade Merial animal health for most of Boehringer Ingelheim’s OTC drug and supplement business as both drug makers look to build critical mass in key diversified areas. Consumer healthcare is poised to become Sanofi’s second top-selling franchise after diabetes.
You may also be interested in...
Sanofi Goes Public With Hostile Medivation Bid
Oncology asset fits with CEO Brandicourt's reorganization, but firms like Astellas, AbbVie and AstraZeneca may also be interested.
Meet The New $200bn Normal In M&A, EY Says
Pharmaceutical sector will continue to fill in growth gaps, consulting firm says in new report.
Deal Watch: Sanofi, Boehringer Swap Side Businesses
Busy week for AstraZeneca sees buyout of Acerta and acquisition of remaining Daliresp/Daxas worldwide rights from Takeda. Amgen and GSK undo their cancer drug alliances from 2009 and 2010, with all rights reverting to the big biotech.